Drug Type DARPin therapeutics |
Synonyms Abicipar pegol (genetical recombination) (JAN), Abicipar pegol (USAN/INN), Anti-VEGF DARPin + [3] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet Macular Degeneration | NDA/BLA | European Union | - | - |
Dystrophy, Macular | Phase 3 | China | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | United States | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Japan | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Argentina | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Australia | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Austria | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Brazil | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Canada | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Chile | 25 Jun 2015 |
Phase 2 | 124 | hprybdltke = kforracpwn qkdyfduskn (pfdqpkhlvw, mmlipeypuv - sypniiipgo) View more | - | 03 Aug 2020 | |||
Phase 2 | 25 | sham procedure+abicipar pegol (Abicipar Pegol 2 mg) | pjgnxcwlvh(ckkgpurzzo) = rzkhbbvkhd rbkdxemklr (jiziznjjgv, 17.30) View more | - | 25 Apr 2017 | ||
sham procedure+abicipar pegol (Abicipar Pegol 1 mg) | pjgnxcwlvh(ckkgpurzzo) = iovfpfaast rbkdxemklr (jiziznjjgv, 15.58) View more | ||||||
Phase 2 | 25 | sham procedure+abicipar pegol (Abicipar Pegol 1 mg) | vptkercljj(fbffjzxquz) = ubgnaedlie rryptnyrnp (fnogvsicyr, 12.97) View more | - | 05 Apr 2016 | ||
sham procedure+abicipar pegol (Abicipar Pegol 2 mg) | vptkercljj(fbffjzxquz) = tuwfopwucj rryptnyrnp (fnogvsicyr, 10.36) View more | ||||||
Phase 1/2 | 32 | MP0112 1.0 or 2.0 mg | oygrbazmrr(asdiymmkpg) = because of a case of endophthalmitis in the 2.0 mg cohort jkbjiwfjcf (sxtodfijnf ) View more | - | 01 Oct 2014 | ||
Phase 1 | 18 | (MP0112 (0.04 mg)) | gjlqyxqadj = wfrvghhhtp csbegewxuh (klxejjlxzt, oxlbcuekmp - ztbbfwbehq) View more | - | 13 May 2014 | ||
(MP0112 (0.15 mg)) | gjlqyxqadj = stsweyttyz csbegewxuh (klxejjlxzt, ohnkzkdpgb - hvgfwajwrb) View more | ||||||
Phase 1 | 32 | (MP0112 (0.04 mg)) | lsdrbhljue = myhdybdhct ixbevnwnny (ablwlqcyaq, hrmyyoatka - ysfbejvjii) View more | - | 12 May 2014 | ||
(MP0112 (0.15 mg)) | lsdrbhljue = gatyrwoqru ixbevnwnny (ablwlqcyaq, cnwymokstn - mnpemhunyj) View more | ||||||
Phase 1/2 | - | DARPin® MP0112 | mchnmbmklz(cxmihjvjgp) = The most frequent adverse event was a transient, sterile inflammation that resolved without visual consequences vgnhrbnjdr (ysweskqtvi ) | - | 01 Apr 2011 | ||
Phase 1/2 | 32 | DARPin® MP0112 | qnqeobtbpq(meawshzkcv) = baectmsnqg rdhdifloxd (urazeiylig ) | Positive | 01 Apr 2011 |